Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN KEMPERS

NPI
1003852427
CMS profile
237
Location
FRIDLEY, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$45.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $45.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Bausch Health US, LLC $45.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN KEMPERS

NPI 1003852427 · CMS profile ID 237

FRIDLEY, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003852427?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN KEMPERS, NPI 1003852427, CMS profile ID 237. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003852427?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). STEVEN KEMPERS, NPI 1003852427, CMS profile ID 237. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003852427?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
STEVEN KEMPERS, NPI 1003852427, CMS profile ID 237, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1003852427?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $45.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bausch Health US, LLC $45.0006/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851581007 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $487.41 9
PY2020 $2,100.00 1
PY2021 $45.00 1
PY2022 $197.59 3
PY2023 $8,088.76 14
PY2024 $2,182.90 6
PY2025 $2,500.00 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $625,552.01 94
PY2024 Principal investigator $714,642.60 239
PY2023 Principal investigator $556,939.59 143
PY2022 Recipient $155.00 1
PY2022 Principal investigator $633,017.42 68
PY2021 Recipient $29,455.27 2
PY2021 Principal investigator $881,507.91 62
PY2020 Principal investigator $539,612.47 58
PY2019 Recipient $15,973.75 2
PY2019 Principal investigator $1,131,652.54 72

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

58 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AbbVie Inc. $5,662.80 12/30/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M15-997 No dispute reported 06/30/2026 721203987
Principal investigator 1 Galderma Research & Development, LLC $5,000.00 12/29/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO COMPARE EFFICACY AND SAFETY OF TRIFAROTENE (CD5789) CREAM WHEN USED WITH AN ORAL ANTIBIOTIC FOR THE TREATMENT OF SEVERE ACNE VULGARIS No dispute reported 06/30/2026 725257057
Principal investigator 1 Incyte Corporation $10,443.83 12/18/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744303081
Principal investigator 1 Janssen Research & Development, LLC $2,675.00 12/14/2020 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis No dispute reported 06/30/2026 719485099
Principal investigator 1 Merck Sharp & Dohme Corporation $12,300.00 12/14/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety,Tolerability of Subcutaneous SCH 900222,MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis Protocol No. MK-3222-010 No dispute reported 06/30/2026 740822405
Principal investigator 1 Bausch Health US, LLC $4,591.00 12/10/2020 Non-covered Recipient Individual A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IDP-124 LOTION FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN PEDIATRIC AND ADULT SUBJECTS No dispute reported 06/30/2026 737375431
Principal investigator 1 AbbVie Inc. $2,650.40 12/04/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M16-833 No dispute reported 06/30/2026 721199665
Principal investigator 1 AbbVie Inc. $3,000.00 12/01/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M16-833 No dispute reported 06/30/2026 721198461
Principal investigator 1 Amgen Inc. $9,429.40 12/01/2020 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIST PADBA MINNESOTA CLINIC STUDY CTR
Efficacy/Safety study of Apremilast in subjects with Mild-to-moderate Plaque Psoriasis (PSOR-022) No dispute reported 06/30/2026 731627298
Principal investigator 1 AbbVie Inc. $8,282.30 11/30/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M15-997 No dispute reported 06/30/2026 721197659
Principal investigator 1 Incyte Corporation $11,750.97 11/27/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744303069
Principal investigator 1 Eli Lilly and Company $3,500.00 11/19/2020 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 728731657
Principal investigator 1 Incyte Corporation $15,583.76 11/03/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744303067
Principal investigator 1 AbbVie Inc. $2,324.10 10/06/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M16-833 No dispute reported 06/30/2026 721190189
Principal investigator 1 AbbVie Inc. $4,930.90 09/30/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M15-997 No dispute reported 06/30/2026 721189397
Principal investigator 1 Incyte Corporation $16,934.57 09/25/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744303063
Principal investigator 1 VYNE Pharmaceuticals Inc. $6,155.34 09/10/2020 Non-covered Recipient Entity
Associated Skincare Specialists dba Minnesota Clinical Study
FX2016-40 No dispute reported 06/30/2026 753088951
Principal investigator 1 AbbVie Inc. $1,089.90 09/03/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M16-833 No dispute reported 06/30/2026 721185067
Principal investigator 1 Incyte Corporation $19,101.76 09/01/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744303061
Principal investigator 1 AbbVie Inc. $9,155.90 08/28/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M15-997 No dispute reported 06/30/2026 721183721
Principal investigator 1 Galderma Research & Development, LLC $2,500.00 08/28/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO COMPARE EFFICACY AND SAFETY OF TRIFAROTENE (CD5789) CREAM WHEN USED WITH AN ORAL ANTIBIOTIC FOR THE TREATMENT OF SEVERE ACNE VULGARIS No dispute reported 06/30/2026 725256881
Principal investigator 1 Eli Lilly and Company $38,570.40 08/13/2020 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 728732725
Principal investigator 1 AbbVie Inc. $5,551.50 08/05/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M16-833 No dispute reported 06/30/2026 721179717
Principal investigator 1 Incyte Corporation $5,203.35 08/03/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744303059
Principal investigator 1 AbbVie Inc. $2,831.40 07/30/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M15-997 No dispute reported 06/30/2026 721178367
Principal investigator 1 Bausch Health US, LLC $3,075.00 07/30/2020 Non-covered Recipient Individual A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IDP-124 LOTION FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN PEDIATRIC AND ADULT SUBJECTS No dispute reported 06/30/2026 737374905
Principal investigator 1 Janssen Research & Development, LLC $4,731.00 07/27/2020 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis No dispute reported 06/30/2026 719485095
Principal investigator 1 VYNE Pharmaceuticals Inc. $3,250.00 07/16/2020 Non-covered Recipient Entity
Associated Skincare Specialists dba Minnesota Clinical Study
FX2016-40 No dispute reported 06/30/2026 753088955
Principal investigator 1 VYNE Pharmaceuticals Inc. $1,321.00 07/16/2020 Non-covered Recipient Entity
Associated Skincare Specialists dba Minnesota Clinical Study
FX2016-40 No dispute reported 06/30/2026 753088959
Principal investigator 1 AbbVie Inc. $1,958.30 07/07/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M16-833 No dispute reported 06/30/2026 721175145
Principal investigator 1 AbbVie Inc. $6,836.70 07/01/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M15-997 No dispute reported 06/30/2026 721174185
Principal investigator 1 AbbVie Inc. $3,045.70 06/04/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M16-833 No dispute reported 06/30/2026 721170261
Principal investigator 1 AbbVie Inc. $5,644.60 05/29/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M15-997 No dispute reported 06/30/2026 721168879
Principal investigator 1 Bausch Health US, LLC $3,844.00 05/29/2020 Non-covered Recipient Individual A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IDP-124 LOTION FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN PEDIATRIC AND ADULT SUBJECTS No dispute reported 06/30/2026 737374601
Principal investigator 1 VYNE Pharmaceuticals Inc. $7,646.60 05/28/2020 Non-covered Recipient Entity
Associated Skincare Specialists dba Minnesota Clinical Study
FX2016-40 No dispute reported 06/30/2026 753088965
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,069.30 05/19/2020 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA MINNESOTA CLINICAL STUDY CENTER
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EXTENSION STUDY OF SUBCUTANEOUS SECUKINUMAB TO DEMONSTRATE LONG-TERM EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 753932448
Principal investigator 1 Dermira, Inc. $19,857.30 05/07/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 736908985
Principal investigator 1 AbbVie Inc. $1,979.60 05/06/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M16-833 No dispute reported 06/30/2026 721165287
Principal investigator 1 AbbVie Inc. $2,535.00 04/30/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M15-997 No dispute reported 06/30/2026 721164195
Principal investigator 1 AbbVie Inc. $7,983.75 04/03/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M16-833 No dispute reported 06/30/2026 721159861
Principal investigator 1 Incyte Corporation $4,423.00 04/02/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744303057
Principal investigator 1 AbbVie Inc. $11,585.60 03/30/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M15-997 No dispute reported 06/30/2026 721158843
Principal investigator 1 VYNE Pharmaceuticals Inc. $4,555.72 03/13/2020 Non-covered Recipient Entity
Associated Skincare Specialists dba Minnesota Clinical Study
FX2016-40 No dispute reported 06/30/2026 753088949
Principal investigator 1 AbbVie Inc. $1,676.30 03/05/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M16-833 No dispute reported 06/30/2026 721154697
Principal investigator 1 AbbVie Inc. $1,267.50 02/28/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M15-997 No dispute reported 06/30/2026 721153691
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $18,418.14 02/19/2020 Non-covered Recipient Entity
Associated Skin Care Specialists - Minnesota Clinical Study Center
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 736758895
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $29,099.89 02/11/2020 Non-covered Recipient Entity
Associated Skin Care Specialists - Minnesota Clinical Study Center
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis No dispute reported 06/30/2026 736758897
Principal investigator 1 VYNE Pharmaceuticals Inc. $5,700.61 02/10/2020 Non-covered Recipient Entity
Associated Skincare Specialists dba Minnesota Clinical Study
FX2016-40 No dispute reported 06/30/2026 753088961
Principal investigator 1 AbbVie Inc. $4,162.50 02/05/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M16-833 No dispute reported 06/30/2026 721149803
Principal investigator 1 AbbVie Inc. $4,855.50 01/30/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M15-997 No dispute reported 06/30/2026 721148543
Principal investigator 1 Amgen Inc. $33,742.90 01/29/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
Efficacy/Safety study of Apremilast in subjects with Mild-to-moderate Plaque Psoriasis (PSOR-022) No dispute reported 06/30/2026 731627453
Principal investigator 1 Janssen Research & Development, LLC $3,378.00 01/27/2020 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis No dispute reported 06/30/2026 719485089
Principal investigator 1 Eli Lilly and Company $83,468.00 01/21/2020 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 728733459
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,668.48 01/15/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED DOUBLE BLIND MULTI CENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF 2 SUBCUTANEOUS SECUKINUMAB DOSE REGIMENS IN ADULT PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA SUNSHINE No dispute reported 06/30/2026 721492231
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,538.43 01/15/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED DOUBLE BLIND MULTICENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF SUBCUTANEOUS SECUKINUMAB IN SUBJECTS OF BODY WEIGHT 90 KG OR HIGHER WITH MODERATE TO SEVERE CHRONIC PLAQUE TYPE PSORIASIS No dispute reported 06/30/2026 721492613
Principal investigator 1 Eli Lilly and Company $5,494.67 01/09/2020 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 728730479
Principal investigator 1 AbbVie Inc. $1,936.80 01/03/2020 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M16-833 No dispute reported 06/30/2026 721144409
Principal investigator 1 Bausch Health US, LLC $1,644.00 01/03/2020 Non-covered Recipient Individual A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IDP-124 LOTION FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN PEDIATRIC AND ADULT SUBJECTS No dispute reported 06/30/2026 737373139